Long Term Complications Following 54 Consecutive Lung Transplants

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2016 Jun 14

PMID 27293842

Citations 6

Authors

Walther Tabarelli

Hugo Bonatti

Dominique Tabarelli

Miriam Eller

Ludwig Muller

Elfriede Ruttmann

Cornelia Lass-Florl

Clara Larcher

Christian Geltner

Affiliations

Soon will be listed here.

Abstract

Background: Due to the complex therapy and the required high level of immunosuppression, lung recipients are at high risk to develop many different long term complications.

Methods: From 1993-2000, a total of 54 lung transplantation (LuTx) were performed at our center. Complications, graft and patient survival of this cohort was retrospectively analyzed.

Results: One/five and ten-year patient survival was 71.4%, 41.2% and 25.4%; at last follow up (4/2010), twelve patients were alive. Of the 39 deceased patients, 26 died from infectious complications. Other causes of death were myocardial infarction (n=1), progressive graft failure (n=1), intracerebral bleeding (n=2), basilary vein thrombosis (n=1), pulmonary emboli (n=1), others (n=7). Surgical complication rate was 27.7% during the first year and 25% for the 12 long term survivors. Perioperative rejection rate was 35%, and 91.6% for the 12 patients currently alive. Infection incidence during first hospitalization was 79.6% (1.3 episodes per transplant) and 100% for long term survivors. Commonly isolated pathogens were cytomegalovirus (56.8%), Aspergillus (29.4%), RSV (13.7%). Other common complications were renal failure (56.8%), osteoporosis (54.9%), hypertension (45%), diabetes mellitus (19.6%).

Conclusions: Infection and rejection remain the most common complications following LuTx with many other events to be considered.

Citing Articles

Occurrence rate and risk factors for acute kidney injury after lung transplantation: a systematic review and meta-analysis.

Lee N, Ying H PeerJ. 2025; 13:e18364.

PMID: 39995987 PMC: 11849521. DOI: 10.7717/peerj.18364.

Successfully physical therapy program for functional respiratory rehabilitation after lung transplant surgery - case report.

Tache-Codreanu D, David I, Popp C, Bobocea L, Traistaru M Rom J Morphol Embryol. 2024; 65(2):331-340.

PMID: 39020549 PMC: 11384042. DOI: 10.47162/RJME.65.2.21.

Low Prevalence of HLA-G Antibodies in Lung Transplant Patients Detected using MAIPA-Adapted Protocol.

Pedini P, Hubert L, Carlini F, Baudey J, Tous A, Jordier F Int J Mol Sci. 2023; 24(22).

PMID: 38003669 PMC: 10671704. DOI: 10.3390/ijms242216479.

Conditioned Medium from Human Amnion-Derived Mesenchymal Stromal/Stem Cells Attenuating the Effects of Cold Ischemia-Reperfusion Injury in an In Vitro Model Using Human Alveolar Epithelial Cells.

Miceli V, Bertani A, Chinnici C, Bulati M, Pampalone M, Amico G Int J Mol Sci. 2021; 22(2).

PMID: 33419219 PMC: 7825633. DOI: 10.3390/ijms22020510.

A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses.

Bailey E, Zemke J, Choi J, Gray G Front Immunol. 2020; 10:2861.

PMID: 31921130 PMC: 6930876. DOI: 10.3389/fimmu.2019.02861.

References

McCartney J, Meyer K . Optimizing post-transplant outcomes in lung transplantation. Expert Rev Respir Med. 2010; 2(2):183-99. DOI: 10.1586/17476348.2.2.183. View

. [The registry report of Japanese lung transplantation--2009]. Nihon Kokyuki Gakkai Zasshi. 2010; 48(7):546-9. View

Murray S, Charbeneau J, Marshall B, LiPuma J . Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(4):363-71. DOI: 10.1164/rccm.200712-1834OC. View

Zamora M . Cytomegalovirus and lung transplantation. Am J Transplant. 2004; 4(8):1219-26. DOI: 10.1111/j.1600-6143.2004.00505.x. View

Jaksch P, Zweytick B, Kerschner H, Hoda A, Keplinger M, Lang G . Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant. 2009; 28(7):670-5. DOI: 10.1016/j.healun.2009.03.012. View

Delgado M, Fernandez R, Paradela M, de la Torre M, Gonzalez D, Garcia J . Development of neoplasms during lung transplantation follow-up. Transplant Proc. 2008; 40(9):3094-6. DOI: 10.1016/j.transproceed.2008.08.090. View

Christie J, Edwards L, Aurora P, Dobbels F, Kirk R, Rahmel A . Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report--2008. J Heart Lung Transplant. 2008; 27(9):957-69. DOI: 10.1016/j.healun.2008.07.018. View

Yousem S, Berry G, Cagle P, Chamberlain D, Husain A, Hruban R . Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1996; 15(1 Pt 1):1-15. View

De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.... Clin Infect Dis. 2008; 46(12):1813-21. PMC: 2671227. DOI: 10.1086/588660. View

10.

Kaiser L, Aubert J, Pache J, Deffernez C, Rochat T, Garbino J . Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006; 174(12):1392-9. DOI: 10.1164/rccm.200604-489OC. View

11.

Avery R . Infections after lung transplantation. Semin Respir Crit Care Med. 2006; 27(5):544-51. DOI: 10.1055/s-2006-954612. View

12.

Gerbase M, Soccal P, Spiliopoulos A, Nicod L, Rochat T . Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2008; 27(8):898-904. DOI: 10.1016/j.healun.2008.04.012. View

13.

Evon D, Burker E, Galanko J, Dedert E, Egan T . Depressive symptoms and mortality in lung transplant. Clin Transplant. 2010; 24(5):E201-6. DOI: 10.1111/j.1399-0012.2010.01236.x. View

14.

Westall G, Michaelides A, Williams T, Snell G, Kotsimbos T . Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation. 2003; 75(12):2064-8. DOI: 10.1097/01.TP.0000069234.04901.A3. View

15.

Iversen M, Burton C, Vand S, Skovfoged L, Carlsen J, Milman N . Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007; 26(12):879-86. DOI: 10.1007/s10096-007-0376-3. View

16.

Sathy S, Martinu T, Youens K, Lawrence C, Howell D, Palmer S . Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. Am J Transplant. 2008; 8(9):1951-6. DOI: 10.1111/j.1600-6143.2008.02345.x. View

17.

Bakker N, Verschuuren E, Erasmus M, Hepkema B, Veeger N, Kallenberg C . Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation. 2007; 83(4):433-8. DOI: 10.1097/01.tp.0000252784.60159.96. View

18.

Arthurs S, Eid A, Deziel P, Marshall W, Cassivi S, Walker R . The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant. 2009; 24(3):341-8. DOI: 10.1111/j.1399-0012.2009.01076.x. View

19.

Bonatti H, Sifri C, Larcher C, Schneeberger S, Kotton C, Geltner C . Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients. Surg Infect (Larchmt). 2016; 18(2):128-136. DOI: 10.1089/sur.2015.266. View

20.

Korzeniewska A, Dyla T, Kosacka M, Jankowska R . [The most common infections of lung allografts]. Pneumonol Alergol Pol. 2009; 77(4):400-6. View